MENU
+Compare
AVIR
Stock ticker: NASDAQ
AS OF
Jul 22, 01:41 PM (EDT)
Price
$3.44
Change
+$0.01 (+0.29%)
Capitalization
293.54M

AVIR Atea Pharmaceuticals Forecast, Technical & Fundamental Analysis

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections... Show more

Industry: #Biotechnology
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AVIR with price predictions
Jul 21, 2025

AVIR sees MACD Histogram just turned negative

AVIR saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on July 15, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 36 instances where the indicator turned negative. In of the 36 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for AVIR moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AVIR as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVIR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The 50-day moving average for AVIR moved above the 200-day moving average on July 16, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AVIR advanced for three days, in of 247 cases, the price rose further within the following month. The odds of a continued upward trend are .

AVIR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 134 cases where AVIR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.714) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). AVIR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (274.844).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. AVIR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVIR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
AVIR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AVIR is expected to report earnings to rise 3.62% to -41 cents per share on August 06

Atea Pharmaceuticals AVIR Stock Earnings Reports
Q2'25
Est.
$-0.41
Q1'25
Beat
by $0.01
Q4'24
Missed
by $0.05
Q3'24
Beat
by $0.06
Q2'24
Beat
by $0.18
The last earnings report on May 12 showed earnings per share of -40 cents, beating the estimate of -40 cents. With 141.34K shares outstanding, the current market capitalization sits at 293.54M.
A.I. Advisor
published General Information

General Information

a developer of vaccines

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
225 Franklin Street
Phone
+1 857 284-8891
Employees
75
Web
https://www.ateapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
USREF0.540.03
+6.06%
TACTICAL RES CORP.
MAQAF3.49N/A
N/A
Atlas Arteria Ltd.
PZCUY1.38N/A
N/A
PZ Cussons Plc.
ATSKF0.88N/A
N/A
Allied Telesis Holdings KK
LZAGY70.04-0.82
-1.16%
Lonza Group AG

AVIR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AVIR has been loosely correlated with XENE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if AVIR jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AVIR
1D Price
Change %
AVIR100%
+2.08%
XENE - AVIR
47%
Loosely correlated
-0.32%
MGTX - AVIR
44%
Loosely correlated
+0.81%
IMNM - AVIR
44%
Loosely correlated
+2.27%
FHTX - AVIR
44%
Loosely correlated
-0.49%
AURA - AVIR
44%
Loosely correlated
+0.89%
More